Aventura, FL, United States of America

Ottrina S Bond

This inventor holds 1 USPTO granted patent. Top assignee: Opko Pharmaceuticals, LLC. Active years: 2013.


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Ottrina S Bond

Introduction

Ottrina S Bond is a notable inventor based in Aventura, FL (US). He has made significant contributions to the field of medical science, particularly in the area of targeted therapies for diseases related to angiogenesis. His work focuses on the development of innovative solutions that can potentially transform treatment options for various conditions.

Latest Patents

Ottrina S Bond holds a patent for "Compositions and methods for selective inhibition of VEGF." This patent discloses siRNA compositions and methods that are useful for inhibiting the expression of vascular endothelial growth factor (VEGF) isoforms. The compositions are designed to selectively target angiogenic VEGF isoforms while sparing anti-angiogenic isoforms. This innovation has the potential to treat diseases that involve angiogenesis stimulated by the overexpression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and various types of cancer.

Career Highlights

Ottrina S Bond is currently associated with Opko Pharmaceuticals, LLC, where he continues to advance his research and development efforts. His work is pivotal in the ongoing quest to find effective treatments for diseases that significantly impact patient quality of life.

Collaborations

He collaborates with esteemed colleagues such as Phillip Frost and Nadine Dejneka, who contribute to the innovative environment at Opko Pharmaceuticals. Their combined expertise fosters a culture of creativity and scientific advancement.

Conclusion

Ottrina S Bond's contributions to the field of medical science through his innovative patent on VEGF inhibition exemplify the impact of targeted therapies in treating complex diseases. His ongoing work at Opko Pharmaceuticals continues to inspire advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…